Evaluation of AFP expression as a predictive marker for response to anti-VEGFR-2 inhibition

Date 28 June 2017
Event ESMO World Congress on Gastrointestinal Cancer 2017
Session ESMO World Congress on Gastrointestinal Cancer 2017
Topics Gastrointestinal Cancers
Translational Research
Biomarkers
Presenter Linda Lee
Citation Annals of Oncology (2017) 28 (suppl_3): iii13-iii136. 10.1093/annonc/mdx261
Authors L. Lee, L. Huber, J. Stewart, M. Mathews, B. Falcon
  • /

Abstract

Ramucirumab is a fully human monoclonal IgG1 antibody that specifically targets vascular endothelial growth factor receptor 2 (VEGFR-2). In the phase 3, randomized REACH study in patients with advanced hepatocellular carcinoma (HCC) following first-line sorafenib, Ramucirumab improved median overall survival in a prespecified subgroup of patients who had a baseline a-fetoprotein (AFP) level of 400 ng/mL or greater. HCC patients with high baseline AFP typically have a very poor prognosis and have tumors that exhibit a more aggressive and invasive phenotype. Relationship between the AFP levels and response to anti-angiogenics (ramucirumab) in HCC is not well understood.